| 2026-08-05 | Press release | Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-04 | Deck | Rapport Corporate Presentation, August 2026 |
| 2026-06-10 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-20 | Press release | Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global H |
| 2026-05-07 | Press release | Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-23 | Proxy | Definitive proxy statement |
| 2026-04-21 | Press release | Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seiz |
| 2026-04-21 | 8-K | Form 8-K, Item 7.01 |
| 2026-04-01 | Press release | Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 Ame |
| 2026-03-10 | Press release | Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-03-10 | Press release | Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-03-10 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-10 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-09 | Press release | Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercializatio |
| 2026-02-24 | Press release | Rapport Therapeutics to Participate in Upcoming Investor Conferences |
| 2026-01-07 | Press release | Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and C |
| 2026-01-07 | 8-K | Form 8-K, Item 7.01 |
| 2026-01-07 | 8-K | Form 8-K, Item 8.01 |
| 2025-11-06 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-06 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-09-10 | 8-K | Form 8-K, Item 1.01 |
| 2025-09-08 | 8-K | Form 8-K, Item 7.01 |
| 2025-09-08 | 8-K | Form 8-K, Item 8.01 |
| Transcript | Earnings call transcript |
| 2025-08-07 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-07 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-06-18 | 8-K | Form 8-K, Item 5.07 |
| 2025-06-02 | 8-K | Form 8-K, Item 7.01 |
| 2025-05-08 | 8-K | Form 8-K, Item 2.02 results |
| 2025-05-08 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2025-04-24 | Proxy | Definitive proxy statement |
| 2025-03-11 | 8-K | Form 8-K, Item 2.02 results |
| 2025-03-11 | 10-K | Annual report on Form 10-K, FY24 |
| 2025-03-03 | 8-K | Form 8-K, Item 7.01 |
| 2025-01-10 | 8-K | Form 8-K, Item 7.01 |
| 2024-11-07 | 8-K | Form 8-K, Item 2.02 results |